Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471662 | 0.89 | CYP3A4 (0.43) | CYP3A4ALDH1A1KDM4ESMN1; SMN2ROCK2 | |
| SCHEMBL9989725 | 0.88 | ALDH1A1 (0.38) | CYP3A4ALDH1A1ROCK2POLBNUDT1 | |
| SCHEMBL2473765 | 0.83 | POLB (0.48) | CYP3A4ALDH1A1KDM4ESMN1; SMN2ROCK2 | |
| SCHEMBL2476635 | 0.80 | POLB (0.41) | CYP3A4ALDH1A1KDM4ESMN1; SMN2ROCK2 | |
| SCHEMBL2478187 | 0.76 | ALDH1A1 (0.43) | CYP3A4ALDH1A1ROCK2POLB | |
| SCHEMBL9988581 | 0.76 | POLB (0.50) | CYP3A4ALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL2476563 | 0.76 | POLB (0.46) | CYP3A4ALDH1A1KDM4ESMN1; SMN2ROCK2 | |
| SCHEMBL28421816 | 0.75 | ROCK2 (0.35) | CYP3A4ALDH1A1KDM4EROCK2 | |
| SCHEMBL27520390 | 0.72 | ALDH1A1 (0.52) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL23804548 | 0.71 | CYP3A4 (0.40) | CYP3A4ALDH1A1SMN1; SMN2ROCK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373633-B1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | BOREALIS AGROLINZ MELAMINE (AT) | 2014-04-16 | — | — | EP | disclosed |
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2011-12-01 | — | — | US | disclosed |
| EP-2373633-A1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | Borealis Agrolinz Melamine GmbH (AT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066683-A1 | METHOD FOR PRODUCING TRAZINE CARBAMATES USING CHLOROFORMATES | BOREALIS AGROLINZ MELAMINE GMBH (AT) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295001-A1 | Method for Producing Triazine Carbamates Using Chloroformates | CA3, CA7, KAT5 | CYP3A4 464/4885ALDH1A1 1014/4885KDM4E 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.